Benzinga · Feb 26, 2024
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
4 analysts have expressed a variety of opinions on Harpoon Therapeutics (NASDAQ:HARP) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Harpoon Therapeutics, revealing an average target of $20.25, a high estimate of $23.00, and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 86.98% increase from the previous average price target of $10.83. Decoding Analyst Ratings: A Detailed Look A comprehensive examination of how financial experts perceive Harpoon Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yigal Nochomovitz Citigroup Raises Neutral $23.00 $13.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Neutral $23.00 $12.00 Hartaj Singh Oppenheimer Announces Outperform $23.00 - Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $12.00 $7.50 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or ...Full story available on Benzinga.com
